XOMA Corp. Price Target Raised to $9.00 at RBC Capital (XOMA)
Equities researchers at RBC Capital lifted their price target on shares of XOMA Corp. (NASDAQ:XOMA) from $7.00 to $9.00 in a research report issued on Thursday, AnalystRatings.Net reports. The firm currently has an “outperform” rating on the stock. RBC Capital’s target price would suggest a potential upside of 99.56% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at MLV Capital raised their price target on shares of XOMA Corp. from $7.50 to $8.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Piper Jaffray Cos. initiated coverage on shares of XOMA Corp. in a research note to investors on Monday, August 12th. They set an “overweight” rating and a $8.00 price target on the stock. Finally, analysts at Roth Capital raised their price target on shares of XOMA Corp. from $5.00 to $6.00 in a research note to investors on Friday, August 9th. Five investment analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $7.00.
Shares of XOMA Corp. (NASDAQ:XOMA) traded up 3.20% during mid-day trading on Thursday, hitting $4.51. 3,102,922 shares of the company’s stock traded hands. XOMA Corp. has a one year low of $2.37 and a one year high of $5.53. The stock has a 50-day moving average of $4.69 and a 200-day moving average of $4.28. The company’s market cap is $375.0 million.
XOMA Corp. (NASDAQ:XOMA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.02. The company had revenue of $7.20 million for the quarter, compared to the consensus estimate of $9.30 million. During the same quarter in the previous year, the company posted ($0.24) earnings per share. Analysts expect that XOMA Corp. will post $-0.86 EPS for the current fiscal year.
XOMA Corporation (NASDAQ:XOMA) is engaged in the discovery and development of antibody-based therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.